Change - Announcement of Appointment::Announcement of Appointment

Issuer & Securities

Issuer/ Manager
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
Securities
TIANJIN PHARM DA REN TANG GRP - CNE100000924 - T14
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
30-Dec-2022 18:05:19
Status
New
Announcement Sub Title
Announcement of Appointment
Announcement Reference
SG221230OTHRC2X0
Submitted By (Co./ Ind. Name)
Jiao Yan
Designation
Secretary to the Board
Description (Please provide a detailed description of the event in the box below)
Announcement of Appointment of Director

Additional Details

Date Of Appointment
30/12/2022
Name Of Person
Mao Weiwen
Age
48
Country Of Principal Residence
China
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
Approved

Ms. Mao was recommended to the Nomination Committee of the Company by TPH (the Controlling Shareholder of the Company as at the Latest Practicable Date) to act as a non-executive Director of the Company. Upon assessment by the Nomination Committee, the Nomination Committee is of the view that Ms. Mao is qualified to act as a Director of the Company and agreed to submit the proposed appointment of Ms. Mao as a Director of the Company to the Board for consideration and approval. The independent Directors of the Company for the time being have examined the nomination procedures and Ms. Mao's qualifications, and are of the view that the nomination procedures of Ms. Mao comply with the Articles of Association of the Company. The Board approved the proposed appointment of Ms. Mao as a Director of the Company and the proposed appointment of Ms. Mao as a Director of the Company shall be submitted for Shareholders approval at the EGM.
Whether appointment is executive, and if so, the area of responsibility
Duties as a Non-Executive Director of the Company
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Non-Executive and Non-Independent Director
Professional qualifications
Ms. Mao Weiwen is a senior economist and a certified human resource professional (level 1), and obtained a postgraduate degree in organisation and human resource management from the University of Hong Kong and a MBA degree from Lingnan University.
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
During the period from May 2021 to December 2021, Ms. Mao worked as the Human Resources Director of TPH (the Controlling Shareholder of the Company as at the Latest Practicable Date) and since December 2021, she has been working as the Chief Human Resources Officer of TPH.
Conflict of interests (including any competing business)
Nil
Working experience and occupation(s) during the past 10 years
From March 2009 to February 2014, she served as the General Manager of the Human Resources Department of Shanghai Pharmaceutical Holdings Co., Ltd. and from March 2014 to May 2021, she was appointed as a Director and Executive Vice President of Shanghai Shengyuan Group. During the period from May 2021 to December 2021, Ms. Mao worked as the Human Resources Director of TPH (a Controlling Shareholder of the Company as at the date of this Circular) and since December 2021, she has been working as the Chief Human Resources Officer of TPH (the Controlling Shareholder of the Company as at the Latest Practicable Date).
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
No
Other Principal Commitments* Including Directorships#
*"Principal Commitments" has the same meaning as defined in the Code
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
From March 2014 to May 2021, Ms. Mao Weiwen was appointed as a Director of Shanghai Shengyuan Group.
Present
Nil
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Disclosure applicable to the appointment of Director only.
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
The Company will arrange for Ms. Mao Weiwen to attend training on the roles and responsibilities of a director of a listed issuer as prescribed by the SGX-ST, in accordance with Rule 210(5)(a) and Practice Note 2.3 of the Listing Manual of the SGX-ST.
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
N.A.